Cellectis (NASDAQ:CLLS) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Cellectis (NASDAQ:CLLS) posted its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04, Zacks reports. The company had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Cellectis Trading Up 0.5%

CLLS stock traded up $0.01 during midday trading on Monday, reaching $1.48. The company’s stock had a trading volume of 19,203 shares, compared to its average volume of 53,090. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61. Cellectis has a 52 week low of $1.25 and a 52 week high of $5.48. The stock has a market cap of $148.30 million, a PE ratio of -2.24 and a beta of 2.92. The business’s 50-day simple moving average is $2.74 and its 200-day simple moving average is $3.19.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, September 15th. Robert W. Baird cut their price objective on Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, September 15th. Citizens Jmp restated a “market perform” rating on shares of Cellectis in a research report on Tuesday, September 15th. Barclays downgraded Cellectis from an “overweight” rating to an “underweight” rating and lowered their target price for the company from $9.00 to $1.30 in a research note on Wednesday, September 16th. Finally, Weiss Ratings downgraded Cellectis from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.46.

About Cellectis

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.